Lu Wang

Dr. Lu Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2022 in Chinese Journal of Natural Medicines
Verified
Journal Article
Closed access
LWLu Wang
Lu Wang
GHGui-Zhou Hu
Gui-Zhou Hu
YLYin Lu
Yin Lu
SJShu-Jun Jiang
Shu-Jun Jiang
JQJin Qi
Jin Qi
HSHua Su
Hua Su

4 July 2025 in Biochemical Pharmacology
Verified
Journal Article
Closed access
JCJingwei Cui
Jingwei Cui
HCHao Chen
Hao Chen
YCYuru Chen
Yuru Chen
BZBingwen Zhou
Bingwen Zhou
CHChuyue Huang
Chuyue Huang
LWLu Wang
Lu Wang

27 October 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BZBingwen Zhou
Bingwen Zhou
QLQingrui Liu
Qingrui Liu
CHChuyue Huang
Chuyue Huang
HCHao Chen
Hao Chen
PWPei Wang
Pei Wang
ZFZhimin Fan
Zhimin Fan
The adenoma-adenocarcinoma pathway represents a crucial mechanism underlying the development of colorectal precancerous lesions, encompassing approximately 85%-90% of colorectal cancer (CRC). Elucidating the molecular mechanisms underlying colorectal cancer progression is of paramount importance for achieving early and accurate diagnosis as well as effective treatment. We collected peripheral blood mononuclear cells (PBMC) from healthy controls, adenoma patients, and adenocarcinoma patients, and performed transcriptomic profiling to characterize dynamic gene expression during carcinogenesis. Diagnostic potential was assessed using receiver operating characteristic (ROC) analysis, and a random-forest model was trained to classify disease status. The screening identified genes with consistent expression changes as potential early diagnostic markers, and further exploration of their functions and significance in CRC is conducted through analysis of the TCGA database. The findings revealed that the progression of precancerous lesions in the “Normal-Adenoma-Cancer” (N-A-C) sequence was accompanied by a sustained enhancement of the immune response. Notably, HECW2, WARS1, SLC16A3, SECTM1, IFITM3, ADAMTSL4, FCGR1A, F2RL1, OPLAH, SERPINA1, FCGR1CP showed consistent upregulation with promising diagnostic performance. In our PBMC cohort, the random-forest classifier achieved an accuracy of 93.62%, indicating potential for distinguishing cancer from precancerous lesions. The bioinformatics analysis revealed a significant association of these genes with DNA methyltransferase, DNA mismatch repair, m6A regulator, tumor mutational burden (TMB) and microsatellite instability (MSI). Furthermore, a detailed analysis was further performed on WARS1. In the “N-A-C” sequence, WARS1 exhibited a significant upregulation in both blood and tissues, demonstrating a positive correlation with augmented infiltration of immune cells, activation of stromal and immune responses, as well as heightened activity during the cancer immune cycle. However, it demonstrates a declining trend in the progression of CRC from stage I to IV, which may be intricately associated with the metastasis of CRC. The WARS1 can serve as a reliable indicator of the immune response in CRC, thereby demonstrating its potential to impede tumorigenesis or metastasis.

8 October 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
YYYueying Yang
Yueying Yang
YLYang Liu
Yang Liu
LWLu Wang
Lu Wang
JLJing Liang
Jing Liang
HZHongyan Zhang
Hongyan Zhang
LCLixia Chen
Lixia Chen
Drug resistance seriously affects the treatment effect and survival rate of colorectal cancer (CRC) patients. The discovery of novel drugs and mechanisms is an important way to overcome drug resistance. Here, Tubocapsenolide A (TA), a major withanolide isolated from Tubocapsicum anomalum, significantly inhibited the growth of patient-derived organoids with oxaliplatin or 5-fluorouracil resistance and HCT116-/DLD-1-derived xenografts. Leveraging Proteolysis Targeting Chimera (PROTAC)-based target identification approach, PLK1 was identified as a direct target of TA. Mechanistically, PLK1 was first determined as a p53 cytoplasmic anchoring factor to prevent p53 from inducing ferroptosis in CRC. TA competitively inhibits the formation of PLK1-p53 heterodimers, promotes the nuclear translocation of p53, and then activates ferroptosis. Collectively, our study clarified the key role of PLK1 in p53-mediated ferroptosis for the first time and elucidated a novel mechanism of TA as a natural ferroptosis inducer in CRC treatment. The activation of the PLK1-p53-ferroptosis signaling axis may provide a brand-new strategy for the treatment of CRC.

1 April 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
BZBingwen Zhou
Bingwen Zhou
JPJinjin Pan
Jinjin Pan
MWMengjie Wang
Mengjie Wang
PZPeng Zhou
Peng Zhou
ZLZhili Li
Zhili Li
ZFZhimin Fan
Zhimin Fan
Paclitaxel, a natural diterpenoid compound derived from Taxus species, is one of the most successful plant-based anticancer drugs and has been widely applied in the treatment of various solid tumors. In recent years, emerging evidence has suggested its potential efficacy in refractory or advanced colorectal cancer (CRC), particularly in patients resistant to standard first-line chemotherapy such as 5-fluorouracil (5-FU). However, responses to paclitaxel in CRC are heterogeneous. This study aimed to elucidate the metabolic determinants underlying the heterogeneous response of CRC to paclitaxel and to identify serum metabolites associated with therapeutic response. Integrated serum metabolomic profiling was performed in patient-derived tumor organoid (PDTOs, n=18), combined with drug sensitivity assays and in vivo validation using mouse xenograft models. An analysis was conducted to sensitivity of paclitaxel, followed by targeted metabolomic quantification and pathway enrichment to identify key metabolites influencing paclitaxel efficacy. Linoleic acid (LA) was identified as a serum metabolite significantly correlated with reduced paclitaxel sensitivity. Elevated LA levels attenuated paclitaxel-induced G2/M cell cycle arrest and reduced cytotoxicity by altering microtubule dynamics. Functional validation in CRC cell lines and animal models further confirmed that LA diminished the antitumor effect of paclitaxel, supporting a metabolism-mediated mechanism of chemoresistance. This study identifies serum linoleic acid as a metabolism-related candidate biomarker associated with paclitaxel resistance in CRC. These findings highlight the potential clinical relevance of metabolic factors in modulating chemotherapy response and suggest that LA may have potential relevance for patient stratification in future studies of paclitaxel response in CRC.

28 May 2026 in Chinese Medicine
Verified
Journal Article
Open access
LWLu Wang
Lu Wang
QLQing-Rui Liu
Qing-Rui Liu
BZBing-Wen Zhou
Bing-Wen Zhou
CHChu-Yue Huang
Chu-Yue Huang
PDPing-Gang Ding
Ping-Gang Ding
ZFZhimin Fan
Zhimin Fan
Background: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with resistance to oxaliplatin (Oxa) and its associated side effects posing major therapeutic challenges. Natural flavonoids have shown potential in the prevention and treatment of CRC. Purpose: This study aimed to investigate whether combining Oxa with the bioactive flavonoid licoisoflavone A (LA) derived from Glycyrrhiza species could exert enhanced antitumor effects against CRC and to explore the underlying mechanisms. Methods: A CT26 tumor-bearing mouse model was established to evaluate the therapeutic efficacy of Oxa in combination with LA in vivo. Mass spectrometry-based proteomics and metabolomics analyses were performed to identify differentially expressed proteins and metabolites between the Oxa group and the Oxa plus LA group. Differential expressed proteins and associated pathways were subsequently validated in HCT116 cells, SW480 cells, and patient-derived organoids. Furthermore, two complex organoid models—an organoid–lymphocyte co-culture system and an air–liquid interface organoid system—were developed to investigate the underlying mechanisms. Flow cytometry and Western blot analyses were employed in both in vitro and in vivo settings. Results: The combination of LA and Oxa significantly inhibited tumor growth in CT26 tumor-bearing mice. Arginine metabolism was significantly reduced following LA treatment. Arginase-1 (ARG1) was identified as a potential target of LA. LA significantly downregulated ARG1 expression, which was associated with an increased proportion of CD8⁺ T cells and reduced expression of CD69⁺ and PD-1, suggesting a potential alleviation of T cell exhaustion-related features. Moreover, LA inhibited CRC cell proliferation by suppressing ARG1-mediated activation of the PI3K/Akt/mTOR signaling pathway. Conclusions: LA is a natural flavonoid that targets arginine metabolism and enhances the therapeutic efficacy of Oxa in CRC treatment.